Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information

v3.20.1
Note 13 - Segment Information
9 Months Ended
Mar. 31, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 13. Segment Information:

 

The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses.  The Protein Sciences and Diagnostics and Genomics segments both include consumables, instruments, services and royalty revenue.

 

The following is financial information relating to the Company's reportable segments (in thousands):

 

   

Quarter Ended

   

Nine Months Ended

 
   

March 31,

   

March 31,

 
   

2020

   

2019

   

2020

   

2019

 

Net sales:

                               

Protein Sciences

  $ 145,509     $ 137,935     $ 428,021     $ 399,787  

Diagnostics and Genomics

    49,411       47,134       135,808       123,144  

Intersegment

    (240

)

    (208

)

    (972

)

    (590

)

Consolidated net sales

  $ 194,680     $ 184,861     $ 562,857     $ 522,341  

Operating income:

                               

Protein Sciences

  $ 65,046     $ 62,256     $ 185,456     $ 175,821  

Diagnostics and Genomics

    7,062       3,579

 

    8,937       5,061  

Segment operating income

  $ 72,108     $ 65,835     $ 194,393     $ 180,882  

Costs recognized on sale of acquired inventory

    -       (935

)

    -       (2,804

)

Amortization of acquisition related intangible assets

    (15,459

)

    (14,400

)

    (45,467

)

    (43,678

)

Acquisition related expenses

    322       -

 

    (107

)

    (2,973

)

Stock based compensation

    (8,088

)

    (5,725

)

    (27,505

)

    (24,151

)

Corporate general, selling, and administrative expenses

    (1,092

)

    (685

)

    (3,205

)

    (3,821

)

Consolidated operating income

  $ 47,791     $ 44,090     $ 118,109     $ 103,455